TICKERNERD
Menu
XAIRXAIRHealthcare · Medical Devices

XAIR Stock Forecast: Beyond Air, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.31

The 2 Wall Street analysts covering Beyond Air, Inc. hold a median 12-month price target of $20 — +765.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.5M
Ticker Nerd rank
36 / 100
Median analyst target
$20
Analysts covering
2
Revenue$1.8M+0.5% y/y
Operating income−$6.6M
Net income−$8.2M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

XAIR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Beyond Air, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Accruals
86
Revisions
67
Growth
65
Quality
37
Volatility
31
Value
12
Issuance
3
Momentum
2

Size (99): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XAIR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XAIR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $10Median $20High $30

The green dot is the last close — the median target sits +765.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Sept 2026Lake StreetInitiatesBuy$10
27 Mar 2026D. Boral CapitalMaintainsBuy$10
27 Mar 2026D. Boral CapitalMaintainsBuy—
18 Mar 2026D. Boral CapitalMaintainsBuy—
10 Mar 2026D. Boral CapitalMaintainsBuy—
21 Jan 2026D. Boral CapitalMaintainsBuy—
11 Nov 2025D. Boral CapitalMaintainsBuy—
21 Aug 2025D. Boral CapitalMaintainsBuy—
13 Aug 2025D. Boral CapitalMaintainsBuy—
17 July 2025D. Boral CapitalInitiatesBuy—
16 Aug 2024Roth MKMReinstatesBuy$2.00
7 Aug 2024Piper SandlerMaintainsOverweight—
25 June 2024BTIGDowngradeNeutral—
25 June 2024Piper SandlerMaintainsOverweight—
30 Apr 2024Truist SecuritiesMaintainsBuy—
14 Nov 2023Truist SecuritiesMaintainsBuy—
28 July 2023Piper SandlerInitiatesOverweight—
21 July 2023Truist SecuritiesMaintainsBuy—
23 June 2023OppenheimerMaintainsOutperform—
15 June 2023BTIGInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XAIR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

XAIR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Beyond Air, Inc. (XAIR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
0.3×

Cheaper than 87% of US stocks

Price / book
1.0×

Cheaper than 73% of US stocks

EV / EBITDA
−0.7×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
0.5%

Higher than 28% of US stocks

Earnings growth (YoY)
0.5%

Higher than 36% of US stocks

Gross margin
12.7%

Higher than 12% of US stocks

Operating margin
−374.0%

Higher than 8% of US stocks

Net margin
3.3%

Higher than 56% of US stocks

Returns & dividend
Return on equity
−519.5%

Higher than 3% of US stocks

Return on assets
−57.5%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Beyond Air, Inc. (XAIR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Beyond Air, Inc. has a market value of $2.5M and an enterprise value of $17.1M.

  • Revenue in the twelve months to 30 June 2026: $7.7M. The latest quarter grew 0.5% year on year.

  • Net income over the same four quarters: −$34.4M, a −447.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−277.40.

  • Free cash flow in the twelve months to 30 June 2026: −$19.6M.

  • Shares outstanding: 743,418.

  • Trailing P/E: 0.0×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Beyond Air, Inc. employs 54 people — $142K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

XAIR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
XAIRBeyond Air, Inc.$2.5M
36
VJETFlyte Aviation, Inc.$2.1M
26
NUWENuwellis, Inc.$2.5M
15
ADGMAdagio Medical Holdings, Inc.$2.8M
34
NXLNexalin Technology, Inc.$3.4M
33
IVFINVO Fertility, Inc.$3.5M
31
BJDXBluejay Diagnostics, Inc.$3.6M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Beyond Air, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XAIR news & analysis

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

GlobeNewsWire · 8 Oct 2026positive

Beyond Air reported preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, its highest quarterly revenue, up about 30% sequentially and 27% year over year. The company attributed performance to continued adoption of first-generation LungFit PH, noted that its second-generation system remains under FDA review, and reaffirmed its 2026 and 2027 revenue guidance.

Why it matters — The update gives XAIR watchers a read on recent LungFit PH adoption and the company's reaffirmed revenue outlook, while the next-generation system remains under FDA review.

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference

GlobeNewsWire · 2 Sept 2026neutral

Beyond Air, Inc. announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, scheduled for September 9-11, 2026, at the Waldorf Astoria New York. The company stated the news in a press release on September 2, 2026.

Why it matters — Conference participation gives XAIR watchers an opportunity to hear management discuss the company's nitric oxide-focused platform and strategy directly with investors.

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

GlobeNewsWire · 31 Aug 2026positive

Beyond Air, Inc. announced that the U.S. Food and Drug Administration granted Breakthrough Device Designation to its LungFit GO device for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). The designation was announced on August 31, 2026.

Why it matters — The FDA Breakthrough Device Designation for LungFit GO may facilitate a faster regulatory review path for the company's nitric oxide-based treatment in a new indication, expanding Beyond Air's potential therapeutic applications.

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

GlobeNewsWire · 25 Aug 2026neutral

Beyond Air, Inc. has entered into a definitive agreement to sell its NeuroNOS stake to UNIVO Pharmaceutical Industries. Upon closing, Beyond Air will receive shares representing 19.99% of UNIVO's issued and outstanding share capital, and is eligible to receive up to $32.5 million in development and commercial milestone payments.

Why it matters — XAIR watchers would track this divestiture as it changes Beyond Air's asset portfolio while providing the company potential equity in UNIVO and future milestone-based revenue from the NeuroNOS sale.

Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Beyond Air, Inc. held its Q1 2027 earnings call, which was transcribed by Seeking Alpha.

Why it matters — Earnings calls provide investors and analysts with management's perspective on quarterly financial results and operational progress.

FAQ

Frequently asked questions about XAIR stock

What is the XAIR stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Beyond Air, Inc. have a median 12-month price target of $20, with estimates ranging from $10 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XAIR stock a buy right now?

Of the 2 analysts covering Beyond Air, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beyond Air, Inc. 36 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XAIR?

As at 8 Oct 2026, Beyond Air, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

Will XAIR stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +765.8% from the last close, and Ticker Nerd's factor model ranks Beyond Air, Inc. 36 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XAIR stock forecast for 2030?

No analyst covering Beyond Air, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XAIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $30 over the next 12 months.

What does Beyond Air, Inc. do?

Beyond Air Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide-based therapies and delivery systems.

What is the latest news on XAIR?

The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026". Beyond Air reported preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, its highest quarterly revenue, up about 30% sequentially and 27% year over year. The company attributed performance to continued adoption of first-generation LungFit PH, noted that its second-generation system remains under FDA review, and reaffirmed its 2026 and 2027 revenue guidance.

Company

About Beyond Air, Inc.

Beyond Air Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide-based therapies and delivery systems. The company’s core LungFit platform generates nitric oxide from ambient air and delivers it in a controlled way for respiratory care, with applications centered on neonatal respiratory conditions and other serious lung diseases. Beyond Air also operates development programs aimed at extending its nitric oxide technology across additional respiratory, neurological, and oncology-related uses. Its business is organized around Beyond Air, Beyond Cancer, and NeuroNos, reflecting a broader platform approach that combines device engineering with therapeutic development. Headquartered in Garden City, New York, Beyond Air serves the healthcare market through products and programs designed for hospital-based clinical use and specialized medical treatment settings.

CEO Mr. Robert Scott Goodman · 54 employees · United States · https://www.beyondair.net